alt

XIX International AIDS Conference (AIDS 2012)

July 2012, Washington, DC

AIDS 2012: Long-acting HIV Integrase Inhibitor S/GSK1265744 May Allow Monthly Dosing

A nano-suspension formulation of the next-generation integrase inhibitor S/GSK1265744 demonstrated a half-life 21 to 50 days after a single injection, suggesting that once-monthly or even less frequent dosing may be possible, according to a poster presentation at the XIX International AIDS Conference (AIDS 2012) recently held in Washington, DC.alt

Read more:

AIDS 2012: French Cohort Treated during Primary Infection Appears to Control HIV without ART

A group of French HIV patients known as the VISCONTI cohort, who started antiretroviral therapy (ART) during the earliest stage of infection, so far appear to be controlling the virus after interrupting treatment, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.

alt

Read more:

AIDS 2012: HDAC Vorinostat Disrupts HIV Latency in Patients' CD4 Cells

The histone deacetylase inhibitor vorinostat can interfere with a mechanisms that allows HIV to remain latent in resting CD4 T-cells, offering the potential to flush out the virus -- one approach being explored as a potential cure for HIV, researchers reported in the July 25, 2012, issue of Nature and at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC.alt

Read more:

New Guidance Addresses Expanded Antiretroviral Treatment, Perinatal ART, PrEP

On the occasion of the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC, the International Antiviral Society-USA (IAS-USA) released new guidelines recommending that all people diagnosed with HIV should be offered antiretroviral therapy (ART).alt

Read more:

AIDS 2012: HIV Drugs Cheaper than Thought, Clinton Report Says

Antiretroviral therapy and related care for people with HIV worldwide would likely cost about 4 times less than previously estimated, meaning that wider global scale-up of treatment is possible, according to a new report by the Clinton Health Access Initiative released ahead of the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC. alt

Read more: